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These observations triggered the usage of multiple arte-
rial conduits for CABG.3
The radial artery was first introduced as an alternative
arterial conduit in the early 1970s,4 only to be aban-
doned shortly thereafter because of early graft failure
related to accelerated intimal hyperplasia and
vasospasm.5 The use of the radial artery was recently
rejuvenated with encouraging early results attributed to
modifications in harvesting techniques and routine pro-
T he superior long-term patency rate of internal tho-racic artery compared with saphenous vein for coro-
nary artery bypass grafting (CABG) is well document-
ed.1 Improved patency rates have been shown to
translate into improved long-term survival and cardiac
event-free survival.1 More recently the use of 2 internal
thoracic grafts, particularly when used for 2 left-sided
coronary arteries, further improves long-term results
compared with use of a single internal thoracic artery.2
Background: Recent reports of improved radial artery patency have been
attributed, in part, to routine use of diltiazem to prevent vasospasm.
However, diltiazem is costly, and its use may be associated with negative
inotropic and chronotropic side effects. This study compares the
vasodilatory properties of diltiazem to those of nitroglycerin. Methods: In
vitro, with the use of organ chambers, the vasodilatory properties of dil-
tiazem and nitroglycerin were compared in matched segments of radial
artery, internal thoracic artery, and saphenous vein that were harvested
from the same patients (n = 11). The vasodilatory response of the radial
artery to intravenous diltiazem or nitroglycerin was compared in vivo (n
= 10) with the use of ultrasonographic measurements of radial artery
diameter. Results: The maximum relaxation of radial artery (100% ±
4%), internal thoracic artery (96% ± 4%), and saphenous vein (100% ±
3%) to nitroglycerin were significantly greater than the response to dil-
tiazem (33% ± 6%, 22% ± 7%, and 34% ± 5%, respectively; P < .001).
The thromboxane mimetic, U46619, induced radial artery spasm with a
median effective concentration of 3.7 ± 0.8 nmol/L. Physiologic concen-
trations of nitroglycerin (0.1 m mol/L) significantly inhibited the radial
artery response to U46619 (median effective concentration, 6.2 ± 1.1
nmol/L; P = .046), whereas diltiazem (1 m mol/L) did not (median effec-
tive concentration, 3.7 ± 0.8 nmol/L; P = .64). In vivo, nitroglycerin
increased radial artery diameter 22% ± 3%, which was significantly
greater than diltiazem (3% ± 0.5%; P = .001). Conclusion: Nitroglycerin
is a superior conduit vasodilator and is more effective in preventing
graft spasm than diltiazem. Nitroglycerin should be strongly considered
as the drug of choice to prevent conduit spasm after coronary bypass
grafting. (J Thorac Cardiovasc Surg 1999;117:906-11)
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longed administration of antispasmodic agents, of
which diltiazem is the most frequently used.6-8
However, diltiazem is costly, and its use may be asso-
ciated with negative inotropic and chronotropic side
effects.9 For example, we have shown that up to 40% of
patients receiving diltiazem therapy require temporary
cardiac pacing in the perioperative period, resulting in
a longer intensive care unit stay.10 In contrast,
Gurevitch and colleagues11 have used long-acting
nitrates as an alternative to diltiazem for prevention of
composite arterial conduit spasm and reported satisfac-
tory clinical results.
This study was designed to compare the vasodilatory
and antispasmodic properties of diltiazem to those of
nitroglycerin. In vitro response was assessed with the
use of organ-chamber methods, and in vivo response
was assessed by the use of ultrasonographic measure-
ment of radial artery vasodilation in patients with
known coronary artery disease.
Patients and methods
Patients. For the in vitro studies, matched segments of
radial artery, internal thoracic artery, and saphenous vein that
would otherwise be discarded were obtained from patients (n
= 11) undergoing CABG at Boston Medical Center. Subjects
were included in this study only if segments of all 3 conduits
could be obtained. The study was approved by the Boston
Medical Center Institutional Review Board. The vessels were
harvested with the accompanying fat pedicle and placed in
ice-cold physiologic salt solution (PSS) and prepared imme-
diately for studies of vascular function. For the in vivo stud-
ies, subjects (n = 10) with angiographically documented
coronary artery disease (at least one stenosis of more than
50%) were recruited for assessment of nitroglycerin- and dil-
tiazem-induced dilation of the radial artery.
Materials. The PSS contained the following elements:
NaCl, 118.3 mmol/L; KCl, 4.7 mmol/L; CaCl2, 2.5 mmol/L;
MgSO4, 1.2 mmol/L; KH2PO4, 1.2 mmol/L; NaHCO3, 25
mmol/L; glucose, 11.1 mmol/L; Na2EDTA, 0.026 mmol/L;
and indomethacin, 0.01 mmol/L. Nitroglycerin was obtained
from Baxter Healthcare Corp (Deerfield, Ill). Diltiazem and
U46619 were purchased from Sigma Chemical Co (St Louis,
Mo).
Organ chamber methodology. The vessels were carefully
dissected from their surrounding fat tissue and cut into 2 to 3
rings measuring 4 mm. The rings were placed in organ cham-
bers (37°C) containing 10 mL PSS, suspended between 2
tungsten stirrups for the measurement of isometric tension as
described,12 and constantly aerated with 95% oxygen/5% car-
bon dioxide. Each vessel was then progressively stretched in
1-g increments to its optimal resting tension that produced a
maximal response to 80 mEq of KCl. Vessels were then
allowed to equilibrate for 1 hour before the introduction of
vasoactive drugs as described.13 Relaxation studies were per-
formed after vessels were contracted with 0.1 to 1 m mol/L of
U46619, such that contraction was 50% to 60% of the maxi-
mal KCl-induced contraction. Vessel segments were then
exposed to increasing doses of nitroglycerin or diltiazem
(10–9–10–5 mol/L), and dose-response curves were recorded.
The ability to prevent radial artery spasm was assessed by
dose-response curves to U46619 in baths containing PSS
alone (control) or physiologic concentrations of nitroglycerin
(0.1 µmol/L)14 or diltiazem (1 µmol/L).9
In vivo radial artery vasodilatory studies. The study was
approved by the Boston Medical Center Institutional Review
Board. Subjects were fasted overnight, calcium channel
blockers were withheld for 48 hours before the study, and all
other vasoactive medications were withheld for 24 hours. If
applicable, patients were asked not to smoke overnight before
the study. On the day of the study, images of the radial artery
diameter 5 to 10 cm distal to the antecubital crease were
recorded with an ultrasound system (Toshiba 140a; Toshiba,
American Medical Systems, Tustin, Calif ) equipped with a
7.5 MHz linear array transducer. The transducer position was
marked and used for subsequent scans. Serial 10-minute infu-
sions of intravenous nitroglycerin (0.06–0.36 µmol/min)
were then given into the contralateral arm vein with an infu-
sion pump (Baxter Healthcare Corp, Irvine, Calif). At the end
of each infusion, repeat ultrasound images of the radial artery
were recorded. After a 2-hour period, the radial artery diam-
eter was recorded, and patients were given a 0.25-mg/kg
bolus of diltiazem over 2 minutes, followed by serial 20-
minute diltiazem infusions (0.12-0.36 µmol/min). Radial
artery diameter was determined with the use of customized
image analysis software15 by personnel blinded to infused
medication and image sequence.
Data analysis. Unless otherwise specified, all data are
expressed as mean ± SEM. Vessel relaxation is expressed as
percent reduction in tension induced by U46619. The median
effective dose (EC50) represents the drug concentration pro-
ducing 50% of maximum relaxation/contraction determined
graphically by commercially available software (Origin;
Microcal Inc, Northhampton, Mass). In vitro and in vivo
dose-response curves for nitroglycerin, diltiazem, and
U46619 were compared among the groups using 2-way
analysis of variance (ANOVA) for repeated measures.
Results
Study subjects. Vessel segments for the in vitro
organ-chamber studies were obtained from 11 patients
undergoing CABG. There were 9 men and 2 women,
with a mean age of 56 ± 8 years (range, 39 to 64 years).
No patient received intravenous nitroglycerin before
the operation. A comparable group of 10 subjects were
enrolled in the in vivo ultrasound studies. They were all
men, with a mean age of 61 ± 7 years. The clinical pro-
file of all the study subjects is depicted in Table I.
In vitro vascular relaxation. To determine the rela-
tive vasodilatory properties of diltiazem and nitroglyc-
erin, matched segments of radial artery, internal tho-
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racic artery, and saphenous vein were precontracted
with U46619 and exposed to increasing doses of nitro-
glycerin or diltiazem in organ chambers. The maxi-
mum relaxation of the radial artery (100% ± 4%), inter-
nal thoracic artery (96% ± 4%), and saphenous vein
(100% ± 3%) to nitroglycerin were each significantly
greater than the response to diltiazem (33% ± 6%, 22%
± 7%, and 34% ± 5%, respectively; P < .001; Fig 1).
In vitro prevention of radial artery spasm. To
determine the antispasmodic properties of diltiazem
and nitroglycerin, radial artery segments were placed in
organ chambers containing PSS alone (control) or with
physiologic concentrations of nitroglycerin or dilti-
azem and exposed to increasing doses U46619. The
thromboxane mimetic, U46619, increased radial artery
tone with an EC50 of 3.7 ± 0.8 nmol/L. Physiologic
concentrations of nitroglycerin (0.1 µmol/L) signifi-
cantly inhibited the radial artery response to U46619
(EC50, 6.2 ± 1.1; P = .046), whereas diltiazem (1
µmol/L) did not (EC50, 3.7 ± 0.8 nmol/L; P = .64; Fig
2). These data suggest that nitroglycerin is not only a
more potent vasodilator but that it is also more effective
in preventing radial artery spasm than is diltiazem.
In vivo radial vasodilation. Because isolated vessels
may not completely reflect events in vivo, the radial
artery vasodilatory response to intravenous nitroglyc-
erin or diltiazem was compared in vivo with the use of
ultrasonographic measurements of radial artery diame-
ter in subjects with documented coronary artery dis-
ease. Intravenous nitroglycerin produced dose-depen-
dent radial artery vasodilation (P = .001), although
intravenous diltiazem had no vasodilatory effect (P =
.59; Fig 3, A). Maximum increase in radial artery diam-
eter in response to nitroglycerin (22% ± 3%) was much
greater than to diltiazem (3% ± 0.5%; P = .001).
Intravenous nitroglycerin (P = .001) and intravenous
diltiazem (P = .001) both produced a dose-dependent
fall in mean blood pressure (Fig 3, B). The fall in blood
pressure was significantly greater in response to nitro-
glycerin than in response to diltiazem (P = .03, by
repeated-measurements ANOVA). The radial artery
vasodilatory response to nitroglycerin and diltiazem in
a representative subject is depicted in Fig 4.
The order of intravenous vasodilator administration
in this study was not randomized because of the rela-
tively long duration of diltiazem action. Even though
radial artery diameter and systemic blood pressure
returned to baseline between infusions, it is conceiv-
able that the lack of radial artery dilation to diltiazem
reflected some effect of the earlier nitroglycerin infu-
sion. To address this concern, 6 patients returned for a
repeat study of the response to diltiazem without previ-
ous nitroglycerin exposure. Diltiazem had no signifi-
Fig 1. Effect of nitroglycerin and diltiazem on radial artery (A), internal thoracic artery (B), and saphenous vein
(C). Segments of radial artery, internal thoracic artery, and saphenous vein obtained from the same patients and
contracted with 0.1 to 1 µmol/L U46619. Relaxation was recorded in response to the indicated doses of nitro-
glycerin and diltiazem as described in the text. Data are expressed as mean ± SEM and represent complete ves-
sel sets derived from 11 patients. *P < .001.
Table I. Clinical profile of the study patients
In vitro studies In vivo studies 
(n = 11) (n = 10)
Age (y) 56 ± 8 61 ± 7
Men (%) 82 100
Diabetes mellitus (%) 45 33
Hypertension (%) 73 60
Cigarette smoking (%) 64 70
Hypercholesterolemia (%) 73 80
Diseased vessels > 50% (n) 2.7 ± 0.4 1.7 ± 0.8
Grafts/patient 3.7 ± 0.6 NA
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cant effect in these subjects, with a change in radial
artery diameter of 0.7% ± 1.2%, 0.5% ± 2.1%, and
–0.1% ± 1.3% in response to diltiazem infusions of
0.12, 0.24, and 0.36 µmol/min, respectively (P = .86, by
repeated-measures ANOVA).
Discussion
The use of the radial artery for coronary revascular-
ization has been recently rejuvenated with improved
early and midterm clinical results.6-8 However, the radi-
al artery propensity for vasospasm documented both
clinically,5,6,16-20 and in studies of isolated arterial seg-
ments with the use of organ-chamber methods,21,22 is
still worrisome. Chardigny and colleagues21 have shown
that radial artery and gastroepiploic artery have greater
contractile response to norepinephrine and serotonin
compared with the internal thoracic artery. He and
Yang22 reported that both endothelin I and angiotensin
II induced significantly higher contraction force in the
radial artery than in the internal thoracic artery. Most
authors emphasize the necessity for pharmacologic
intervention to prevent vasospasm when these conduits
are used.6-8,10,16-22 However, the drug of choice to pre-
vent vasospasm is still a matter of controversy.
The calcium channel blocker diltiazem has been
empirically selected by most surgeons.6-8,10,16-19
However, diltiazem is costly and its use may be associ-
ated with negative inotropic and chronotropic side-
effects.9 Up to 30% to 40% of patients undergoing
CABG and treated with diltiazem may experience
hypotension, bradycardia, or heart block requiring low-
ering the dose, discontinuing the drug, or temporary
pacing.7,10 Moreover, use of diltiazem does not com-
pletely eliminate spasm. In early and midterm angio-
graphic studies radial artery spasm was identified in
1% to 9.7% of cases.6,16-20 Recently, Cable and col-
leagues23 demonstrated that diltiazem and verapamil
had little effect on radial artery receptor-dependent and
Fig 2. Prevention of radial artery vasospasm. A, Radial artery
segments were exposed to the indicated concentrations of
U46619 in organ chambers containing PSS alone (s), 0.1
µmol/L nitroglycerin ( s ), or 1 µmol/L diltiazem (=).
Response to a maximal dose of U46619 was similar for all.
B, However, the EC50 of the vasoconstrictor response to
U46619 was significantly higher for nitroglycerin. Data are
expressed as mean ± SEM and represent data obtained from
6 patients. *P = .046 versus control.
Fig 3. Effect of intravenous nitroglycerin and diltiazem on
radial artery vasodilation and blood pressure (BP). Diltiazem
(d) or nitroglycerin (h) was given intravenously at the indi-
cated rates in 10 subjects. Vasodilation (A) and blood pres-
sure (B) were recorded as described in the text. *P = .001 for
dose-response by one-way repeated measures ANOVA. †P =
.03 vs diltiazem by two-way ANOVA.
A
B
A
B
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receptor-independent contraction, whereas nifedipine
and nitroglycerin were much more effective. In anoth-
er study,24 the authors demonstrated that the use of ver-
apamil and nitroglycerin solution to prepare radial
artery grafts maximally preserves endothelial function.
A systematic comparison of diltiazem to nitroglycerin
has not been previously performed. With this informa-
tion in mind, we sought to compare the vasodilatory
response of the most commonly used coronary bypass
conduits to nitroglycerin to that of diltiazem.
The data presented in this study demonstrate that the
in vitro maximum relaxation of all 3 coronary bypass
conduits to nitroglycerin is significantly greater than
the response of these conduits to the calcium channel
blocker diltiazem. We found diltiazem to be ineffective
in vessels precontracted with U46619. Similar results
were reported in radial arteries precontracted with
potassium chloride or norepinephrine.23 In our study,
these in vitro observations were also found to be valid
in vivo. Intravenous administration of nitroglycerin in
patients with documented coronary artery disease
induced significantly greater increase in radial artery
diameter compared with diltiazem. Finally, within the
therapeutic dose range, nitroglycerin was found to be
much more effective in preventing U46619-induced
radial artery spasm than was diltiazem. In accordance
with our findings, Canver and colleagues25 have recent-
ly used ultrasonography and Doppler studies to docu-
ment strong vasodilatory responses to oral nitroglyc-
erin of both in situ and grafted internal thoracic arter-
ies.
The clinical experience with the use of nitrates for
the specific indication of prevention of arterial conduit
spasm is limited, with only one published report.11
Gurevitch and colleagues11 have used high-dose isosor-
bide dinitrate in patients undergoing myocardial revas-
cularization with composite arterial grafts. They report-
ed hospital mortality rates of 2.6%, postoperative
hypoperfusion syndrome in 2.6% of patients, and a
postoperative myocardial infarction rate of 1.3%. At a
mean follow-up of 24 months, all hospital survivors
were alive, with 97% being angina-free; 97% of the
angiographically studied anastomoses were patent.11
A major potential limitation of the use of nitrates is
the development of tolerance.26 The cause of tolerance
is unclear and is a subject of intense investigation.27 It
is not related to altered pharmacokinetics, because drug
plasma levels remain the same or even higher after pro-
longed use compared with the initial therapy.28
Although there can be no doubt that loss of hemody-
namic effects is a true phenomenon, it is also clear that
some vascular effects of nitrate therapy persist during
continued therapy and that cessation of treatment may
be associated with withdrawal symptoms.26 Similar to
Fig 4. Representative two-dimensional ultrasound images of the radial artery in a volunteer subject exposed to
intravenous infusion of nitroglycerin and diltiazem. A 31% increase in radial artery diameter is observed after
nitroglycerin infusion (upper panels), whereas diltiazem had no measurable effect (lower panels).
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the variability of different vessel responses to nitro-
glycerin,29,30 there are differences in the susceptibility
of veins, arteries, and arterioles to develop nitrate toler-
ance and that arterial or arteriolar response may persist
although venous tolerance exists.30 To eliminate the tol-
erance effect as a confounding factor in the present
study, none of the patients from whom vascular tissues
were obtained for organ-chamber studies received
intravenous nitroglycerin treatment, and oral nitroglyc-
erin medications were withheld for 48 hours in subjects
recruited for the in vivo studies. Undoubtedly, the
mechanism and the clinical implications of tolerance in
this treatment setting need to be further explored.
In conclusion, in this study nitroglycerin was found
to be a superior arterial vasodilator and more effective
in preventing radial artery spasm than diltiazem.
Although a prospective randomized study comparing
these agents clinically is clearly indicated, the data pre-
sented here strongly suggest that nitroglycerin should
be considered as the drug of choice to prevent arterial
conduit spasm after CABG.
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